Skip to content

EBIT at other companies

Haemonetics logo
HaemoneticsHAE
$67.4M+14.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$3.65M+81.1%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
-$31.8M-198%
ADMA Biologics logo
ADMA BiologicsADMA
$58.27M+67.1%
Paysign logo
PaysignPAYS
$6.67M+168%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Calculated from Cerus’s reported figures.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's EBIT?
Cerus (CERS) reported EBIT of -$354K in Q1 2026.
How has Cerus's EBIT changed year-over-year?
Cerus's EBIT increased by 94.0% year-over-year, from -$5.85M to -$354K.
What is the long-term trend for Cerus's EBIT?
Over 4 years (2021 to 2025), Cerus's EBIT has grown at a -35.1% compound annual growth rate (CAGR), from -$48.94M to -$8.68M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.